Skip to main content
Premium Trial:

Request an Annual Quote

Drug Discovery Startup Engine Biosciences Raises $10M

NEW YORK (GenomeWeb) – Drug discovery startup Engine Biosciences announced today that it has raised $10 million in seed funding.

The oversubscribed round was co-led by Danhua Capital and 6 Dimensions Capital, and included WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI Harper, and Nest Bio Ventures.

Engine said it would use the funding to continue development of its drug discovery platform, which combines high-throughput wet lab experimentation with artificial intelligence algorithms, as well as to expand its scientific and executive teams in Singapore and San Francisco. The company also aims to conduct preclinical studies internally and with partners.

"Engine's data-driven platform allows researchers to uncover the critical gene interactions underlying diseases and also test therapies that specifically target these interactions in a faster, cheaper, and more precise fashion than currently possible," Engine Cofounder and CEO Jeffrey Lu said in a statement.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.